Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Poseida Therapeutics (PSTX)
NASDAQ:PSTX
Holding PSTX?
Track your performance easily
PSTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.83 - $4.27
Previous Close$3
Volume446.38K
Average Volume (3M)431.81K
Market Cap
$291.40M
Enterprise Value$137.24M
Total Cash (Recent Filing)$237.81M
Total Debt (Recent Filing)$83.65M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 07, 2024EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding97,120,175
10 Day Avg. Volume264,588
30 Day Avg. Volume431,815
Standard Deviation0.20
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)5.37
Price to Sales (P/S)3.29
Price to Cash Flow (P/CF)1.90
P/FCF Ratio1.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.55
Enterprise Value/Gross Profit2.12
Enterprise Value/Ebitda-2.00
Forecast
1Y Price Target
$15.00Price Target Upside343.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Poseida Therapeutics News
PremiumStock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $10 (or More), Say Analysts
Bulls Say, Bears Say
Bulls Say
FinancialsPoseida will receive a $50M upfront payment and is eligible for up to $550M milestone payments as well as tiered royalties from net sales.
ManagementThe appointment of Dr. Syed Rizvi as chief medical officer, who most recently served as CMO of Caribou Biosciences, strengthens the company's leadership team.
PartnershipThe new partnership brings in non-dilutive funding to support Poseida’s proprietary pipeline development and serves as a strong vote of confidence in its allogeneic CAR-T platform.
Bears Say
Clinical OutcomesOne patient passed away less than 60 days after therapy due to unrelated events, complicating the interpretation of treatment effectiveness.
Strategic DecisionsThe company’s decision to no longer pursue its hybrid delivery candidates will delay its time to the clinic.
Treatment EfficacyA patient who achieved a very good partial response after P-BCMA-ALLO1 treatment progressed approximately 80 days after treatment.
---
Ownership Overview
39.70% Insiders
17.65% Mutual Funds
25.67% Other Institutional Investors
16.99% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PSTX FAQ
What was Poseida Therapeutics’s price range in the past 12 months?
Poseida Therapeutics lowest stock price was $1.83 and its highest was $4.27 in the past 12 months.
What is Poseida Therapeutics’s market cap?
Currently, no data Available
When is Poseida Therapeutics’s upcoming earnings report date?
Poseida Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 50 days.
How were Poseida Therapeutics’s earnings last quarter?
Poseida Therapeutics released its earnings results on Aug 05, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.407 by $0.087.
Is Poseida Therapeutics overvalued?
According to Wall Street analysts Poseida Therapeutics’s price is currently Undervalued.
Does Poseida Therapeutics pay dividends?
Poseida Therapeutics does not currently pay dividends.
What is Poseida Therapeutics’s EPS estimate?
Poseida Therapeutics’s EPS estimate is -$0.42.
How many shares outstanding does Poseida Therapeutics have?
Poseida Therapeutics has 97,133,860 shares outstanding.
What happened to Poseida Therapeutics’s price movement after its last earnings report?
Poseida Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.407. Following the earnings report the stock price went up 3.642%.
Which hedge fund is a major shareholder of Poseida Therapeutics?
Among the largest hedge funds holding Poseida Therapeutics’s share is Aisling Capital Management LP. It holds Poseida Therapeutics’s shares valued at 3M.
---
Poseida Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (343.79% Upside)
$15.00 (343.79% Upside)
Blogger Sentiment
Bullish
PSTX Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 11.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
47.05%
12-Months-Change
Fundamentals
Return on Equity
-115.00%
Trailing 12-Months
Asset Growth
6.21%
Trailing 12-Months
Company Description
Poseida Therapeutics
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors.
---
PSTX Stock 12 Month Forecast
Average Price Target
$15.00
▲(343.79% Upside)
Technical Analysis
Best Analysts Covering PSTX
1 Year
1 Year Success Rate
12/19 ratings generated profit
1 Year Average Return
+5.91%
reiterated a buy rating 5 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +5.91% per trade.
---